schizophrenia

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run (ranging roughly $0.26–$0.84). The stock has surged ~28% on Oct 23 (to $0.5675 markets.financialcontent.com) after a prior drop (–23% on Oct 8 benzinga.com). Recent catalysts include completion of a 1-year Phase 3 trial (brilaroxazine OLE) showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings (~$10M in Q2 and ~$9M in Sept revivapharma.com revivapharma.com) to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy”